MDMA-Assisted Therapy
A PTSD Treatment That Met Its Trial Goals and Was Declined by the FDA
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
Graded grade 3 to grade 4 for PTSD: the Phase 3 evidence of symptom reduction is real and meaningful, but the FDA's 2024 refusal over design, blinding, and conduct issues means the regulatory evidence bar has not yet been cleared, so the grade reflects promising but not yet approved status. A related compound, methylone (TSND-201), received an FDA priority voucher in April 2026, signaling continued federal movement on the broader class.
Reference only. Not medical advice.
What can go wrong
MDMA-assisted therapy carries real risks that the model is built to contain. Acute effects include raised heart rate and blood pressure and temperature dysregulation, making it unsafe for some cardiovascular conditions, and the vulnerability the drug induces creates a serious risk of therapist boundary violations, which is exactly what occurred at one trial site. It is delivered, where legal, under direct supervision with safety monitoring, and is never a self-administration protocol. This is trauma treatment and belongs under qualified clinical care.
This is something to take to a clinician. The Atlas can tell you what is known about mdma-assisted therapy in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
MDMA-assisted therapy is the library's clearest case of a treatment with real trial evidence that still failed a regulatory bar. The compound is modern, synthesized at Merck in 1912, reintroduced by Alexander Shulgin in 1976, and used in 1980s trauma and couples therapy before the DEA placed it on Schedule I in 1985 over therapists' objections, part of the documented post-1970 suppression of psychedelic research. Lykos Therapeutics' Phase 3 trials reduced PTSD symptoms, but in August 2024 the FDA declined approval, citing trial design, the impossibility of blinding an obvious psychedelic, safety-monitoring concerns, and therapist misconduct at one site. The essential honest reading is that this was a rejection about process and conduct, not a verdict that the therapy is ineffective. Switzerland has treated patients under special access for years, and a related compound received an FDA priority voucher in 2026, so the field continues to move.
A therapy whose Phase 3 trials reduced PTSD symptoms and was still declined by the FDA in 2024 on design and conduct grounds, a rejection about process and safety, not a verdict that it does not work.
How it is supposed to work
Proposed and partly characterized: MDMA increases serotonin, along with oxytocin and other signals, producing reduced fear and defensiveness and increased trust and openness, which is thought to let people revisit and reprocess traumatic memories that would otherwise be too overwhelming to approach. The mechanism is plausible and supported by trial outcomes, though the precise neural account and the contribution of the therapy versus the drug remain under study.
What people get wrong
Often saidThe FDA decision means MDMA-assisted therapy does not work.
ActuallyThe 2024 refusal was about trial design, blinding, and conduct, not a finding of ineffectiveness. The symptom-reduction data were real; the regulatory bar was not cleared.
Often saidIt is just taking a party drug in a clinic.
ActuallyThe model is structured psychotherapy across preparatory, dosing, and integration sessions, with the compound as a supervised catalyst, not recreational use.
Who profits, and who pushes back
Lykos Therapeutics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Reports Phase 3 trials showing significant PTSD symptom reduction with MDMA-assisted therapy.
US FDA (2024)
Declined approval citing trial design, functional unblinding, safety monitoring, and site misconduct.
Swiss compassionate-use physicians
Have treated PTSD patients under special access for years in the longest-running program.
Trauma-field critics
Argue blinding and conduct problems require cleaner trials before approval.
Where the research comes from
Most of the published research on this comes from one place. 88% of it is from Switzerland (special access). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Switzerland (special access) | 88% |
| United States (declined 2024) | 84% |
| Canada | 70% |
| Australia | 66% |
How we got here
Unlike most entries in this category, MDMA has no deep Indigenous lineage; it is a modern synthetic compound. It was first synthesized by the chemist Anton Kollisch at Merck in Germany in 1912 and then ignored for decades. The chemist Alexander Shulgin resynthesized and characterized it in 1976 and shared it with therapists, and through the late 1970s and 1980s it was used in couples therapy and trauma work under the name it was given in that community. What it shares with the rest of the ceremonial category is the assisted-therapy model: the compound is a catalyst within a structured psychotherapeutic container, not a daily medication.
MDMA sat unused after its 1912 synthesis until Shulgin reintroduced it in the 1970s and a community of therapists adopted it. Emergency Schedule I placement in 1985 ended sanctioned use, and research only revived through MAPS and later Lykos in the 2000s and 2010s, culminating in Phase 3 trials, the FDA's 2024 refusal, and continued international access and federal signals into 2026.
- 1912Synthesized at Merck, Germany
- 1976Shulgin reintroduces it to therapists
- 1985US DEA emergency Schedule I listing
- 2010s-2020sMAPS and Lykos Phase 3 trials
- Aug 2024FDA declines approval on process grounds
- Apr 2026Related methylone receives FDA priority voucher
How it is understood
MDMA-assisted therapy is delivered in a small number of day-long sessions, with the drug administered under direct supervision by a therapy pair within a course of preparatory and integrative non-drug sessions. The therapeutic relationship and the set and setting are treated as integral to the model rather than incidental.
Where scholars disagree
The dispute is sharp and specific. Lykos Therapeutics ran Phase 3 trials that showed significant PTSD symptom reduction, and proponents argue the treatment is effective and badly needed. In August 2024 the FDA declined to approve it, citing trial design problems, difficulty blinding (participants can tell whether they received an active psychedelic), concerns about safety monitoring, and documented therapist misconduct at one trial site. The key honest point is that the rejection was about trial conduct and process, not a finding that MDMA-assisted therapy is ineffective. Critics and the agency wanted cleaner trials; advocates argued the bar was applied in a way that ignored the difficulty of blinding any psychedelic.
Lykos Therapeutics and MDMA-therapy advocates
MDMA-assisted therapy substantially reduces PTSD symptoms and should be available.
What it rests onPhase 3 trials showing significant symptom reduction versus placebo-with-therapy.
FDA and methodological critics
The trials had design and conduct problems that preclude approval as submitted.
What it rests onFunctional unblinding, safety-monitoring concerns, and therapist misconduct at one site.
This disagreement is live. It has not settled.
At a glance
- First synthesized
- Merck, Germany, 1912
- Reintroduced
- Shulgin, 1976
- DEA Schedule I
- 1985 (emergency)
- FDA decision
- Declined, August 2024 (process)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about MDMA-Assisted Therapy. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.